These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11072612)

  • 1. Thromboangitis obliterans with plasminogen activator inhibitor-1 suppression by PGE1.
    Kikuchi M; Inagaki T
    Clin Exp Rheumatol; 2000; 18(5):647. PubMed ID: 11072612
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to DDAVP stimulation in thirteen patients with Buerger's disease.
    Siguret V; Alhenc-Gelas M; Aiach M; Fiessinger JN; Gaussem P
    Thromb Res; 1997 Apr; 86(1):85-7. PubMed ID: 9172291
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of prostaglandin E1 in chronic obliterative diseases of peripheral arteries].
    Zhang GS
    Zhonghua Wai Ke Za Zhi; 1988 Sep; 26(9):541-2, 573. PubMed ID: 3243146
    [No Abstract]   [Full Text] [Related]  

  • 4. [New aspects of prostaglandin E1 therapeutic influence in thrombo-angiitis obliterans].
    Zdrojowy K; Adamiec R; Czarnacki M
    Pol Arch Med Wewn; 2002 Nov; 108(5):1071-7. PubMed ID: 12685248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of thromboangiitis obliterans with indomethacin].
    Wlodarczykowa J; Kurzawska-Mielecka M; Paczynska D
    Reumatizam; 1977; 24(3):93-6. PubMed ID: 877458
    [No Abstract]   [Full Text] [Related]  

  • 6. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
    Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
    Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Modern aspects of diagnostics and treatment for thromboangiitis obliterans].
    Abyshov NS; Zakirdzhaev EA; Aliev ZM
    Khirurgiia (Mosk); 2009; (2):75-9. PubMed ID: 19368048
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chromatographic analysis of plasmatic 17-ketosteroids in thromboangitis obliterans].
    LOTTI G; MARCENARO A; BIANCHERI V
    Arch Maragliano Patol Clin; 1960 Oct; 16():731-6. PubMed ID: 13763634
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prostaglandin E1 in the treatment of chronic advanced ischemia of the legs before amputation. Mid-term results].
    Fernández-Miranda E; Latorre C; Gil Vera F; González Mate A; Olmos A; Petit J; Durán H
    Rev Quir Esp; 1988; 15(2):67-70. PubMed ID: 3153367
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunoglobulins and complement 3 in patients with thromboangitis obliterans.
    Dasgupta A; Roy MB; Talwar JR; Kapur BM
    Indian J Med Res; 1978 Feb; 67():332-5. PubMed ID: 680892
    [No Abstract]   [Full Text] [Related]  

  • 11. [A role of endothelin 1 in the pathogenesis of thromboangiitis obliterans (initital news)].
    Czarnacki M; Gacka M; Adamiec R
    Przegl Lek; 2004; 61(12):1346-50. PubMed ID: 15850327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [107 patients with thromboangiitis obliterans treated by traditional Chinese medicine combined with Western medicine therapy].
    Pan JY
    Zhong Xi Yi Jie He Za Zhi; 1988 Nov; 8(11):665-7, 646. PubMed ID: 3250763
    [No Abstract]   [Full Text] [Related]  

  • 13. Thromboangiitis obliterans and foot necrosis: A case of successful treatment with alprostadil.
    Silva SP; Azevedo SF; Eugénio G; Barcelos A
    Int J Rheum Dis; 2023 Apr; 26(4):801-802. PubMed ID: 36680434
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemostasis and fibrinolysis in patients with intermittent claudication: effects of prostaglandin E1.
    Weiss C; Regele S; Velich T; Bärtsch P; Weiss T
    Prostaglandins Leukot Essent Fatty Acids; 2000 Nov; 63(5):271-7. PubMed ID: 11090253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Did the arrival of prostanoids modify therapeutic indications in peripheral obstructive arteriopathies? Considerations based on our experience].
    Cardia G; Tumolo R; Cuscito C
    G Chir; 1997 May; 18(5):297-300. PubMed ID: 9312259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study on effects of mailuotong granule on anti-thromboangiitis obliterans].
    Wang J; Wang YS; Fu MH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Jul; 16(7):421-3. PubMed ID: 9387738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intrathrombotic injection of urokinase in Buerger's disease].
    Nakamura K; Tamaoka K; Lin M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1987 Jan; 47(1):82-4. PubMed ID: 3588271
    [No Abstract]   [Full Text] [Related]  

  • 18. [Myocardial infarct in obliterating thromboangitis].
    Gol'dberg GA; Baranova MN; Pruzhanskiĭ IA
    Klin Med (Mosk); 1989 Jul; 67(7):119-20. PubMed ID: 2811201
    [No Abstract]   [Full Text] [Related]  

  • 19. Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors.
    Abeles AM; Nicolescu M; Pinchover Z; Abeles M
    Vascular; 2014 Aug; 22(4):313-6. PubMed ID: 24000082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking and Thromboangitis Obliterans- Are they related ?
    Sapkota P; Budhathoky P; Mathew S
    JNMA J Nepal Med Assoc; 2014; 52(194):802-5. PubMed ID: 26905708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.